Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 84,090 shares of the company's stock, valued at approximately $1,997,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.07% of Surgery Partners as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also made changes to their positions in SGRY. Allianz Asset Management GmbH acquired a new stake in shares of Surgery Partners in the 1st quarter valued at approximately $420,000. DekaBank Deutsche Girozentrale purchased a new position in Surgery Partners during the first quarter worth $65,000. Bank of New York Mellon Corp increased its position in Surgery Partners by 0.3% during the first quarter. Bank of New York Mellon Corp now owns 341,702 shares of the company's stock worth $8,115,000 after buying an additional 926 shares in the last quarter. Principal Financial Group Inc. increased its position in Surgery Partners by 9.5% during the first quarter. Principal Financial Group Inc. now owns 54,266 shares of the company's stock worth $1,289,000 after buying an additional 4,717 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Surgery Partners during the first quarter worth $447,000.
Surgery Partners Stock Performance
SGRY stock traded down $0.67 during trading on Friday, reaching $21.28. 3,103,577 shares of the stock were exchanged, compared to its average volume of 1,323,385. Surgery Partners, Inc. has a twelve month low of $18.87 and a twelve month high of $33.97. The company has a market capitalization of $2.73 billion, a P/E ratio of -13.91 and a beta of 1.82. The stock has a 50 day simple moving average of $22.19 and a 200-day simple moving average of $22.88. The company has a current ratio of 1.89, a quick ratio of 1.73 and a debt-to-equity ratio of 1.09.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $776.00 million during the quarter, compared to analyst estimates of $777.77 million. Surgery Partners had a positive return on equity of 2.41% and a negative net margin of 6.10%. The firm's revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. As a group, sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on SGRY. Barclays reduced their target price on Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 27th. Benchmark reissued a "buy" rating and set a $35.00 price target on shares of Surgery Partners in a research report on Monday, April 21st. Finally, Bank of America assumed coverage on Surgery Partners in a research report on Monday, July 28th. They set a "buy" rating and a $28.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $33.33.
View Our Latest Stock Report on Surgery Partners
Surgery Partners Company Profile
(
Free Report)
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
See Also

Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.